Edison Investment Research Comments on Halozyme Therapeutics on Multiple Value Drivers
Edison Investment Research Comments on Threshold Pharmaceuticals Following Protocol Amendment
UPDATE: Edison Investment Research Initiates Coverage on Solera Holdings on Multiple Positive Factors
Edison Investment Research Comments on Silicom Ltd. on Network Acceleration
Edison Investment Research Recent News
Edison Investment Research Comments on Vertex Pharmaceuticals' VX-661 Data
UPDATE: Edison Investment Research Raises PT on CytRx on FDA Aldoxorubicin Agreement
Edison Investment Research Believes FDA Approval for Sarepta's Eteplirsen Could Come Before Year-End
Edison Investment Research: Oncolytics Biotech's Pending Outcome
Edison: Esterline Technologies' Q1 on Track
Edison Investment Research Comments On Endocyte
Edison Investment Research Comments on Pharmacyclics
Edison Investment Research Publishes Report on Afferro Mining
Edison Investment Research Expects Growth for Ligand Pharmaceuticals
Edison Investment Research Publishes Report on Endocyte
Edison Investment Research Publishes Report on Curis
Edison Investment Research Publishes Investment Summary on OncoGenex Pharmaceuticals
Edison Investment Research Covers Yukon-Nevada Gold
Edison Comments on Micromet
Edison Investment Comments On Synta Pharmaceuticals (SNTA)